G01N33/531

Biomarkers and methods for assessing psoriatic arthritis disease activity

Provided herein are biomarkers and methods for generating scores useful for assessing psoriatic arthritis (PsA) disease activity in subjects previously diagnosed with PsA. The invention also provides predictive model methods based on the biomarkers, as well as computer systems, software embodiments of the models for scoring and optionally classifying samples, and methods of recommending optimal therapeutic regimens.

Modified cardiolipin-coated magnetic nanobeads and preparation methods therefor

Provided in the present invention are a magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof. The magnetic nanosphere coated with modified cardiolipin comprises a modified cardiolipin, a biotin derivative, and a streptavidin magnetic bead. The modified cardiolipin is coupled to the biotin derivative via an —NH—CO structure. The streptavidin magnetic bead is a magnetic nanosphere coupled to streptavidin, and the biotin derivative is coupled to the streptavidin.

Modified cardiolipin-coated magnetic nanobeads and preparation methods therefor

Provided in the present invention are a magnetic nanosphere coated with modified cardiolipin, and manufacturing method thereof. The magnetic nanosphere coated with modified cardiolipin comprises a modified cardiolipin, a biotin derivative, and a streptavidin magnetic bead. The modified cardiolipin is coupled to the biotin derivative via an —NH—CO structure. The streptavidin magnetic bead is a magnetic nanosphere coupled to streptavidin, and the biotin derivative is coupled to the streptavidin.

APPARATUSES, SYSTEMS, AND METHODS FOR SAMPLE TESTING
20230152305 · 2023-05-18 ·

Methods, apparatuses, and systems associated with a sample testing device are provided.

APPARATUSES, SYSTEMS, AND METHODS FOR SAMPLE TESTING
20230152305 · 2023-05-18 ·

Methods, apparatuses, and systems associated with a sample testing device are provided.

QUANTITATION OF FUNCTIONAL GROUPS ON SOLID SUPPORTS

Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

QUANTITATION OF FUNCTIONAL GROUPS ON SOLID SUPPORTS

Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

Method for immobilizing biologic molecules on solid surfaces
09834617 · 2017-12-05 ·

The invention provides a method for immobilization of biological molecules such as nucleic acids, peptides and proteins onto the surface of a glass or plastic solid support.

Method for immobilizing biologic molecules on solid surfaces
09834617 · 2017-12-05 ·

The invention provides a method for immobilization of biological molecules such as nucleic acids, peptides and proteins onto the surface of a glass or plastic solid support.

DILUENT FOR FLUORESCENT NANO PARTICLES, KIT FOR IMMUNOFLUORESCENT STAINING WHICH UTILIZES SAME, SOLUTION FOR IMMUNOFLUORESCENT STAINING, IMMUNOFLUORESCENT STAINING METHOD, AND GENE STAINING METHOD
20170342470 · 2017-11-30 ·

[Problem ] Provided is a means for detecting and quantifying a biological substance of interest with an improved accuracy by inhibiting non-specific adsorption of fluorescent nanoparticles and thereby reducing the background noise in immunostaining with fluorescent nanoparticles. [Means for Solution] Immunostaining is carried out upon diluting fluorescent nanoparticles with a fluorescent nanoparticle diluent which contains 1 to 5% (W/W) of a protein having a molecular weight of 40,000 or higher (e,g., BSA) and 1 to 3% (W/W) of a protein having a molecular weight of less than 40,000 (eg ., casein) and, when casein is used as a low-molecular-weight protein, it is preferred that the κ-casein content in the casein is 10% (W/W) or less and the ratio of α-casein and β-casein (α-casein:β-casein) contained in the casein is 40:60 to 60:40 ( taking the total amount of α-casein and β-casein as 100).